中国现代药物应用
中國現代藥物應用
중국현대약물응용
CHINESE JOURNAL OF MODERN DRUG APPLICATION
2015年
6期
3-4
,共2页
林茂华%唐雨晴%王智辉%钟志超
林茂華%唐雨晴%王智輝%鐘誌超
림무화%당우청%왕지휘%종지초
慢性阻塞性肺疾病%布地奈德%福莫特罗%噻托溴铵
慢性阻塞性肺疾病%佈地奈德%福莫特囉%噻託溴銨
만성조새성폐질병%포지내덕%복막특라%새탁추안
Chronic obstructive pulmonary disease%Budesonide%Formoterol%Tiotropium bromide
目的:研究布地奈德福莫特罗粉吸入剂联合噻托溴铵治疗慢性阻塞性肺疾病(COPD)的临床疗效和安全性。方法90例慢性阻塞性肺疾病患者,随机分为观察组和对照A、B组,每组30例。对照A组接受噻托溴铵治疗,对照B组接受布地奈德/福莫特罗治疗,观察组采用噻托溴铵联合布地奈德/福莫特罗治疗。观察三组治疗效果。结果观察组的一秒用力呼气容积(FEV1)、最大呼气流速(PEF)和FEV1预计百分比,明显优于对照A、B组,差异均具有统计学意义(P<0.05);观察组临床指标较治疗前和对照A、B组更优(P<0.05)。三组患者未见明显不良反应。结论布地奈德/福莫特罗联合噻托溴铵吸入治疗慢性阻塞性肺疾病有利于控制临床症状,改善患者肺功能与生活质量,安全性高。
目的:研究佈地奈德福莫特囉粉吸入劑聯閤噻託溴銨治療慢性阻塞性肺疾病(COPD)的臨床療效和安全性。方法90例慢性阻塞性肺疾病患者,隨機分為觀察組和對照A、B組,每組30例。對照A組接受噻託溴銨治療,對照B組接受佈地奈德/福莫特囉治療,觀察組採用噻託溴銨聯閤佈地奈德/福莫特囉治療。觀察三組治療效果。結果觀察組的一秒用力呼氣容積(FEV1)、最大呼氣流速(PEF)和FEV1預計百分比,明顯優于對照A、B組,差異均具有統計學意義(P<0.05);觀察組臨床指標較治療前和對照A、B組更優(P<0.05)。三組患者未見明顯不良反應。結論佈地奈德/福莫特囉聯閤噻託溴銨吸入治療慢性阻塞性肺疾病有利于控製臨床癥狀,改善患者肺功能與生活質量,安全性高。
목적:연구포지내덕복막특라분흡입제연합새탁추안치료만성조새성폐질병(COPD)적림상료효화안전성。방법90례만성조새성폐질병환자,수궤분위관찰조화대조A、B조,매조30례。대조A조접수새탁추안치료,대조B조접수포지내덕/복막특라치료,관찰조채용새탁추안연합포지내덕/복막특라치료。관찰삼조치료효과。결과관찰조적일초용력호기용적(FEV1)、최대호기류속(PEF)화FEV1예계백분비,명현우우대조A、B조,차이균구유통계학의의(P<0.05);관찰조림상지표교치료전화대조A、B조경우(P<0.05)。삼조환자미견명현불량반응。결론포지내덕/복막특라연합새탁추안흡입치료만성조새성폐질병유리우공제림상증상,개선환자폐공능여생활질량,안전성고。
Objective To study the clinical effect and safety of budesonide/formoterol inhalant combined with tiotropium bromide in the treatment of chronic obstructive pulmonary disease (COPD). Methods A total of 90 COPD patients were randomly divided into observation group, control A group, and control B group, with 30 cases in each group. The control A group received tiotropium bromide for treatment, and control B group received budesonide/formoterol for treatment, while the observation group was treated by budesonide/formoterol combined with tiotropium bromide. Curative effects of the three groups were observed. Results The observation group had remarkably better forced expiratory volume in 1 second (FEV1), peak expiratory flow (PEF), and FEV1 predicted percentage than control A and B groups. The difference had statistical significance (P<0.05). The observation group had better clinical indexes than that before treatment and control A and B groups, and the difference had statistical significance (P<0.05). No obvious adverse reactions were found in all three groups. Conclusion Budesonide/formoterol combined with tiotropium bromide inhalant can effectively control clinical symptoms in treating COPD. It can improve patients’pulmonary function and life quality with high safety.